EP Patent

EP3934632A4 — ESKETAMIN USED TO TREAT DEPRESSION

Assigned to Janssen Pharmaceuticals Inc · Expires 2022-11-23 · 3y expired

What this patent protects

Patent listed against esketamine-hydrochloride.

Drugs covered by this patent

esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3934632A4
Jurisdiction: EP
Classification: —
Expires: 2022-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.